Login
Companies $HYPD
$2.43 -$0.04 (1.62%) After hours
HYPERION DEFI, INC. logo

HYPERION DEFI, INC.

hyperiondefi.com

What Do They Do?

Runs a Hyperliquid validator and offers HYPE-based on-chain services to HYPE holders and clients; also develops ophthalmic delivery technology.

How Do They Make Money?

The company earns HYPE rewards and commissions when its validator successfully validates blocks or transactions, and charges clients for temporary HYPE use, with fees based mainly on trading activity or other use.

revenue
SegmentShareRevenue
Ophthalmic Technology
Sold outright
1.8%
Digital Assets
Usage-based

98%

Who Are Their Customers?

HYPE holders can delegate to its validator, while clients use HYPE through temporary-use arrangements; ophthalmic products are sold to customers.

Do Revenues Turn Into Profits?

No. It lost $45.3M in FY2025.

Operating income, FY2025
−5744% of revenue
▲ +4% (Loss) vs FY2024 (−$48.7M, −85005%)
Net income, FY2025
−5571% of revenue
▲ +9% (Loss) vs FY2024 (−$49.8M, −86889%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +168%
vs $302.5K in Q3 FY2025
Net income
▲ +497%
vs $6.6M in Q3 FY2025
Digital Assets share of revenue vs 100.0% in Q3 FY2025
  • Aug 12, 2026 Sold the remaining legacy life sciences intellectual property The sale to Arctic Vision was completed in July.
  • Jun 5, 2026 Ended the Native Markets deal and wound down the Felix agreement The company planned to move the HYPE used in these arrangements to other strategies.
  • May 14, 2026 Raised full-year adjusted gross profit guidance For full-year 2026, the company raised guidance by approximately 20%.

Shrinking. Revenue fell 94% in 4 years, from $14M in FY2021 to $813.5K in FY2025, about 51% a year.

Shift toward digital assets The older report focused on developing Optejet-based eye therapies and licensing them to partners. The latest report centers on a HYPE treasury, validator operations and on-chain services, alongside ophthalmic development.

Ophthalmic sales scaled back The older report planned to develop and commercialize ophthalmic products itself or with partners; the latest report says it ceased ophthalmic sales efforts but continues Optejet development and registration.

Revenue over time
Ophthalmic Technology Digital Assets
$1M$500K$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support